Wells Fargo’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-81,599
Closed -$1.43M 7742
2020
Q4
$1.43M Buy
81,599
+2,994
+4% +$42K ﹤0.01% 3754
2020
Q3
$919K Sell
78,605
-127,799
-62% -$1.7M ﹤0.01% 3931
2020
Q2
$2.68M Buy
206,404
+84,988
+70% +$1.02M ﹤0.01% 3037
2020
Q1
$1.12M Buy
121,416
+54,676
+82% +$764K ﹤0.01% 3475
2019
Q4
$1.11M Buy
66,740
+26,305
+65% +$427K ﹤0.01% 3791
2019
Q3
$673K Buy
40,435
+3,826
+10% +$52.9K ﹤0.01% 4157
2019
Q2
$503K Sell
36,609
-11,837
-24% -$181K ﹤0.01% 4377
2019
Q1
$834K Buy
48,446
+296
+0.6% +$4.68K ﹤0.01% 4018
2018
Q4
$615K Buy
48,150
+2,330
+5% +$35.3K ﹤0.01% 4210
2018
Q3
$744K Buy
45,820
+4,605
+11% +$65.8K ﹤0.01% 4164
2018
Q2
$531K Sell
41,215
-431
-1% -$5.82K ﹤0.01% 4405
2018
Q1
$518K Sell
41,646
-2,358
-5% -$28.7K ﹤0.01% 4359
2017
Q4
$614K Buy
44,004
+5,284
+14% +$77.4K ﹤0.01% 4247
2017
Q3
$651K Buy
38,720
+9,235
+31% +$150K ﹤0.01% 4152
2017
Q2
$496K Sell
29,485
-36,452
-55% -$545K ﹤0.01% 4225
2017
Q1
$1.02M Buy
65,937
+37,163
+129% +$531K ﹤0.01% 3734
2016
Q4
$430K Buy
28,774
+7,579
+36% +$106K ﹤0.01% 4304
2016
Q3
$266K Buy
21,195
+8,593
+68% +$86.3K ﹤0.01% 4315
2016
Q2
$113K Sell
12,602
-2,613
-17% -$25.6K ﹤0.01% 4751
2016
Q1
$150K Buy
15,215
+520
+4% +$5.33K ﹤0.01% 4586
2015
Q4
$169K Sell
14,695
-213
-1% -$2.64K ﹤0.01% 4564
2015
Q3
$201K Buy
14,908
+98
+0.7% +$1.33K ﹤0.01% 4470
2015
Q2
$205K Sell
14,810
-351,895
-96% -$4.76M ﹤0.01% 4600
2015
Q1
$5.16M Sell
366,705
-75,808
-17% -$1.03M ﹤0.01% 2351
2014
Q4
$6.03M Sell
442,513
-1,685
-0.4% -$23K ﹤0.01% 2198
2014
Q3
$6.78M Buy
444,198
+14,463
+3% +$222K ﹤0.01% 2061
2014
Q2
$7.23M Buy
429,735
+183,798
+75% +$3.31M ﹤0.01% 2060
2014
Q1
$4.94M Buy
245,937
+114,717
+87% +$2.48M ﹤0.01% 2331
2013
Q4
$2.54M Buy
+131,220
New +$2.32M ﹤0.01% 2755

Wells Fargo's OXFD Position: Q1 2021 in Review

Wells Fargo sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 81,599 shares — an estimated $1.43M sold.

Wells Fargo first reported a position in OXFD in Q4 2013 and held it in 29 quarters. The position peaked at $7.23M in Q2 2014. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.

  • Wells Fargo reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • Wells Fargo sold 81,599 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $1.43M.
  • Wells Fargo first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 29 quarters.
  • Wells Fargo's Oxford Immunotec Global PLC Ordinary Shares position peaked at $7.23M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.

Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.